sign in sign up
<<
Home , Isatuximab

POST-TEST

Meet The Professors: Clinical Investigator Perspectives on Key Questions and Emerging Research in the Management of Lymphoma, Chronic Lymphocytic Leukemia and

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING. 1. Final results of the Smart Start trial, 4. In the Phase III RELEVANCE study presented by Westin and colleagues comparing R2 to /chemo- at the 2019 ASCO Annual Meeting, therapy, each followed by maintenance demonstrated the chemotherapy-free rituximab, for patients with previously lead-in with rituximab, and untreated follicular lymphoma, the before the combination with R2 regimen demonstrated ______chemotherapy to be highly effective efficacy. in patients with newly diagnosed a. Equivalent ______diffuse large B-cell b. Inferior lymphoma (DLBCL). c. Superior a. Germinal center B-cell like (GCB) b. Non-GCB 5. Which of the following statements is c. Both a and b true regarding chimeric receptor (CAR) T-cell therapy platforms for 2. Results of the Phase III PHOENIX study DLBCL? published in the Journal of Clinical a. Anti-CD19 CAR T cells have Oncology by Younes and colleagues emerged as effective therapy for evaluating the addition of ibrutinib patients with multiply relapsed/ or placebo to R-CHOP for previously refractory B-cell lymphomas untreated non-GCB DLBCL demon- b. Anti-CD19 CAR T-cell therapies are strated a ______favorable benefit investigational and none is currently with the addition of ibrutinib among FDA approved for the treatment of younger patients compared to older relapsed/refractory DLBCL patients. c. Both a and b a. More d. Neither a nor b b. Less c. Neither a nor b 6. Common adverse events associated with CAR T-cell therapy for patients with R/R 3. The CD79b-directed antibody-drug DLBCL include ______. conjugate was a. Cytokine release syndrome recently FDA approved in combination with ______for patients with DLBCL b. Neurologic toxicities and disease progression after at least 2 c. Both a and b prior therapies. d. Neither a nor b a. /rituximab b. Bendamustine/rituximab 7. Results of the Phase III CASSIOPEIA study evaluating bortezomib, thalidomide c. Bortezomib/rituximab and with or without 2 d. Lenalidomide/rituximab (R ) for transplant-eligible e. Rituximab/CHOP patients with newly diagnosed MM demonstrated a statistically significant improvement in progression-free survival with the daratumumab-containing quadruplet regimen. a. True b. False POST-TEST

Meet The Professors: Clinical Investigator Perspectives on Key Questions and Emerging Research in the Management of Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING. 8. Results of the Phase III MAIA 10. Which of the following drug categories trial evaluating lenalidomide and reflects the mechanism of action of dexamethasone with or without daratu- isatuximab? mumab for transplant-ineligible patients a. Anti-CD38 with newly diagnosed MM ______b. Anti-PD-1/PD-L1 antibody demonstrate a statistically significant c. IMiD (immunomodulatory drug) improvement in progression-free survival with the addition of daratumumab. d. a. Did b. Did not

9. Data from the Phase III COLUMBA trial presented by Mateos and colleagues at the 2019 ASCO Annual Meeting included ______rates of infusion- related reactions with subcutaneous compared to intravenous administration of daratumumab for patients with R/R MM. a. Equivalent b. Significantly higher c. Significantly lower